Search research articles
Contact Us
Filters
Showing results (271-280 of 564) with videos related to
Page
of 57
Sort By:
European Urology
|
May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer
Benjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1993
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors
C N Sternberg, P H de Mulder, A T van Oosterom, et al.
The Journal of Urology
|
November 22, 2017
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Ana M Molina, Thomas E Hutson, Dmitry Nosov, et al.
ESMO Open
|
June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
B Tombal, C N Sternberg, M Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma
Guru Sonpavde, Jonathan E Rosenberg, Noah M Hahn, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 1, 1995
Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer
G Arcangeli, A Micheli, L Verna, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 14, 2006
High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG)
V Pansadoro, P Emiliozzi, F depaula, et al.
Cancer Treatment Reports
|
June 1, 1987
Phase II trial of idarubicin in patients with pancreatic cancer
A Mittelman, G B Magill, V Raymond, et al.
Page
of 57
Search research articles
Search
Showing results (271-280 of 564) with videos related to
Sort By:
Page
of 57
European Urology
|
May 28, 2013
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer
Benjamin A Gartrell, Robert E Coleman, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 1993
Escalated M-VAC chemotherapy and recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) in patients with advanced urothelial tract tumors
C N Sternberg, P H de Mulder, A T van Oosterom, et al.
The Journal of Urology
|
November 22, 2017
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies
Marco Moschini, Shahrokh F Shariat, Morgan Rouprêt, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 17, 2018
Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
Ana M Molina, Thomas E Hutson, Dmitry Nosov, et al.
ESMO Open
|
June 17, 2022
Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
B Tombal, C N Sternberg, M Hussain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma
Guru Sonpavde, Jonathan E Rosenberg, Noah M Hahn, et al.
The Lancet. Oncology
|
February 17, 2019
Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
Bertrand Tombal, Fred Saad, David Penson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
May 1, 1995
Prognostic impact of transurethral resection on patients irradiated for localized prostate cancer
G Arcangeli, A Micheli, L Verna, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
June 14, 2006
High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG)
V Pansadoro, P Emiliozzi, F depaula, et al.
Cancer Treatment Reports
|
June 1, 1987
Phase II trial of idarubicin in patients with pancreatic cancer
A Mittelman, G B Magill, V Raymond, et al.
Page
of 57